Tiaprida,酒精使用障碍的另一种治疗方法:针对一个病例

Q4 Medicine
Luz María González Gualda , Rocío Sáez Povedano , Paloma Cano-Ruiz , Miguel Barberán Navalón
{"title":"Tiaprida,酒精使用障碍的另一种治疗方法:针对一个病例","authors":"Luz María González Gualda ,&nbsp;Rocío Sáez Povedano ,&nbsp;Paloma Cano-Ruiz ,&nbsp;Miguel Barberán Navalón","doi":"10.1016/j.psiq.2023.100393","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Present a clinical case report on the use of tiapride for alcohol detoxification in a patient with a diagnosis of severe alcohol use disorder 303.90 (F10.20).</p></div><div><h3>Clinical case report</h3><p>50 year-old female, under follow-up in the Addictive Behavior Unit from September 2016 to present, with diagnoses of adjustment disorder 309.4 (F43.25)</p><p>Mixed disturbance of emotions or behavior, severe alcohol use disorder 303.90 (F10.20) and severe decompensation, who is treated with tiapride.</p></div><div><h3>Results</h3><p>The studies consulted demonstrate the efficacy and safety of tiapride for alcohol withdrawal syndrome in both outpatient and inpatient settings, in monotherapy or in polytherapy with benzodiazepines and/or antiepileptics, being also used in agitation and/or psychotic symptomatology.</p></div><div><h3>Conclusions</h3><p>In alcohol withdrawal syndrome, tiapride has been found to be effective and can even be considered as an adjunctive treatment to benzodiazepines or anticonvulsants. With a view to the future, pharmacogenetics affecting alcohol use disorder should be taken into account, so that individualized personalized therapy could benefit from fewer adverse effects.</p></div>","PeriodicalId":39337,"journal":{"name":"Psiquiatria Biologica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tiaprida, una alternativa de tratamiento en el trastorno por uso de alcohol: a propósito de un caso\",\"authors\":\"Luz María González Gualda ,&nbsp;Rocío Sáez Povedano ,&nbsp;Paloma Cano-Ruiz ,&nbsp;Miguel Barberán Navalón\",\"doi\":\"10.1016/j.psiq.2023.100393\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>Present a clinical case report on the use of tiapride for alcohol detoxification in a patient with a diagnosis of severe alcohol use disorder 303.90 (F10.20).</p></div><div><h3>Clinical case report</h3><p>50 year-old female, under follow-up in the Addictive Behavior Unit from September 2016 to present, with diagnoses of adjustment disorder 309.4 (F43.25)</p><p>Mixed disturbance of emotions or behavior, severe alcohol use disorder 303.90 (F10.20) and severe decompensation, who is treated with tiapride.</p></div><div><h3>Results</h3><p>The studies consulted demonstrate the efficacy and safety of tiapride for alcohol withdrawal syndrome in both outpatient and inpatient settings, in monotherapy or in polytherapy with benzodiazepines and/or antiepileptics, being also used in agitation and/or psychotic symptomatology.</p></div><div><h3>Conclusions</h3><p>In alcohol withdrawal syndrome, tiapride has been found to be effective and can even be considered as an adjunctive treatment to benzodiazepines or anticonvulsants. With a view to the future, pharmacogenetics affecting alcohol use disorder should be taken into account, so that individualized personalized therapy could benefit from fewer adverse effects.</p></div>\",\"PeriodicalId\":39337,\"journal\":{\"name\":\"Psiquiatria Biologica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psiquiatria Biologica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1134593423000027\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psiquiatria Biologica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1134593423000027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的介绍一例诊断为严重酒精使用障碍的患者使用硫必利进行酒精解毒的临床病例报告303.90(F10.20)。临床病例报告50岁女性,2016年9月至今在成瘾行为科接受随访,诊断为调节障碍309.4(F43.25)情绪或行为混合障碍,严重的酒精使用障碍303.90(F10.20)和严重的失代偿,接受硫必利治疗。结果所咨询的研究证明了硫必利在门诊和住院治疗酒精戒断综合征的有效性和安全性,在苯二氮卓类药物和/或抗癫痫药物的单药或多药治疗中,也可用于躁动和/或精神病症状学。结论在酒精戒断综合征中,硫必利是有效的,甚至可以作为苯二氮卓类药物或抗惊厥药物的辅助治疗。展望未来,应考虑影响酒精使用障碍的药物遗传学,以便个体化个性化治疗能够从更少的不良反应中获益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tiaprida, una alternativa de tratamiento en el trastorno por uso de alcohol: a propósito de un caso

Objective

Present a clinical case report on the use of tiapride for alcohol detoxification in a patient with a diagnosis of severe alcohol use disorder 303.90 (F10.20).

Clinical case report

50 year-old female, under follow-up in the Addictive Behavior Unit from September 2016 to present, with diagnoses of adjustment disorder 309.4 (F43.25)

Mixed disturbance of emotions or behavior, severe alcohol use disorder 303.90 (F10.20) and severe decompensation, who is treated with tiapride.

Results

The studies consulted demonstrate the efficacy and safety of tiapride for alcohol withdrawal syndrome in both outpatient and inpatient settings, in monotherapy or in polytherapy with benzodiazepines and/or antiepileptics, being also used in agitation and/or psychotic symptomatology.

Conclusions

In alcohol withdrawal syndrome, tiapride has been found to be effective and can even be considered as an adjunctive treatment to benzodiazepines or anticonvulsants. With a view to the future, pharmacogenetics affecting alcohol use disorder should be taken into account, so that individualized personalized therapy could benefit from fewer adverse effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Psiquiatria Biologica
Psiquiatria Biologica Medicine-Psychiatry and Mental Health
CiteScore
0.40
自引率
0.00%
发文量
13
期刊介绍: Es la Publicación Oficial de la Sociedad Española de Psiquiatría Biológica. Los recientes avances en el conocimiento de la bioquímica y de la fisiología cerebrales y el progreso en general en el campo de las neurociencias han abierto el camino al desarrollo de la psiquiatría biológica, fundada sobre bases anatomofisiológicas, más sólidas y científicas que la psiquiatría tradicional.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信